Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
Narayan S, Carlson EM, Cheng H, Condon K, Du H, Eckley S, Hu Y, Jiang Y, Kumar V, Lewis BM, Saxton P, Schuck E, Seletsky BM, Tendyke K, Zhang H, Zheng W, Littlefield BA, Towle MJ, Yu MJ.
Narayan S, et al. Among authors: saxton p.
Bioorg Med Chem Lett. 2011 Mar 15;21(6):1634-8. doi: 10.1016/j.bmcl.2011.01.097. Epub 2011 Jan 25.
Bioorg Med Chem Lett. 2011.
PMID: 21324692